© Copyright 2002 Frost & Sullivan. All Rights Reserved. U.S. Emerging Pulmonary Drug Delivery...

© Copyright 2002 Frost & Sullivan. All Rights Reserved.

U.S. Emerging Pulmonary Drug Delivery Technologies Markets

Technological Innovation to Drastically Change

Market Landscape

“The development of path breaking, non-invasive, pulmonary drug delivery technologies such as chlorofluorocarbons (CFC)-free metered dose inhalers

(MDI), dry powder inhalers (DPI), and liquid-based inhalers (LBIs) invites many companies to enter the lucrative market, intensifying competition.”

Pharmaceutical Biotech Analyst Team

Frost & Sullivan


Frost & Sullivan provides:

• Detailed insights into recent developments and trends

• Drivers, restraints, challenges, and strategic recommendations

• Analyst insights on ‘hot topics’ and emerging applications in the market

• Market sizing and competitive analysis

• Market forecasts and opportunity analysis

• Quarterly assessments

• End user analysis within each report

Key Features


• Coverage: The United States

• Proven methodology encompassing extensive primary and secondary data and research

• Focused information and strategies that cover business and technology issues

• Credible data and analysis highlighting industry dynamics

• Winning strategies to help you create precise business plans

What We Offer


Current Market Participants• Find out how you compare to the competition• Assess current and future drivers and restraints• Determine and exploit new market share opportunities

New Entrants • Analyze challenges associated with the industry• Calculate time scales for strategy implementation• Position yourself to capitalize on the market’s unmet needs

Investment Community• Analyze long-term strategies of companies• Determine which participants will outperform the competition• Assess attractiveness of investing in the market

Who Will Benefit?


3M Drug Delivery SystemsAbbott Laboratories (Ross products division)Acrux Ltd.Adaptive Aerosol Delivery Systems/Profile Therapeutics Ltd.Aerogen, Inc.Aeropharm Technology, Inc.Alkermes, Inc.Aradigm Corp.AstraZeneca Pharmaceuticals LPAventis Pharmaceuticals, Inc.Battelle Medical ProductsBespak Plc - Drug Delivery Technologies

BioSante Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc.Chiesi Farmaceutici SpAChiron Corp.Direct-Haler A/SElan Corp., Plc - Drug Delivery SystemsEli Lilly and Co.Emisphere Technologies, Inc.Enzon, Inc.Exhale Therapeutics, Inc.FDA/Center for Drug Evaluation & Research (HFD–7)First Principals, Inc.

Key Market Participants


Generex Biotechnology Corp.GlaxoSmithKline, Inc.Inhale Therapeutic Systems, Inc.LTS LOHMANN Therapie-Systeme AGMicroDose Technologies, Inc.Muro Pharmaceutical, Inc.Nobex Corp.Novo Nordisk A/SOriel Therapeutics, Inc.Ortho McNeil Pharmaceutical, Inc.Pfizer, Inc.Pharmacia Corp.

Profile Therapeutics PlcRespirics, Inc.Schering Plough Corp.Sepracor, Inc.Sheffield Pharmaceuticals, Inc.SkyePharma PlcUnimed Pharmaceuticals, Inc./ Solvay Pharmaceuticals, Inc.Vectura Delivery Devices Ltd.Viasys Healthcare, Inc.ViroPharma, Inc.

Key Market Participants


• Call toll free 877 GO FROST

(877.463.7876)

• Fax toll free 888.690.3329

• E-mail [email protected]

• Visit www.frost.com

For More Information

© Copyright 2002 Frost & Sullivan. All Rights Reserved. U.S. Emerging Pulmonary Drug Delivery...

Documents

Transcript of © Copyright 2002 Frost & Sullivan. All Rights Reserved. U.S. Emerging Pulmonary Drug Delivery...